PubMed Health⌕ Search

Biomedical subjects

S Miyagata

Publications and source records attributed to S Miyagata.

16 recordsLinked to original sources
PubMed1992

[Comparative study on nephrotoxicity of ionic and non-ionic contrast agents for drip infused urography].

The effects on renal function of an ionic and hyperosmolaric contrast agent (diatrizoate) and a non-ionic and slightly hypertonic agent (iohexol) for drip infused urography were compared on 60 patients with normal renal function. Urine samples were collected before and 30 minutes after drip infusion of contrast agent, and analyzed for albumin (ALB), gamma-glutamyl transpeptidase (gamma-GTP), N-acetyl-beta-glucosaminidase (NAG), beta 2 microglobulin (beta 2MG) and creatinine (CRE). The urinary excretion of proteins and enzymes was compared with urinary CRE. gamma-GTP, NAG and beta 2MG increased significantly after infusion of diatrizoate. gamma-GTP and beta 2MG increased significantly after infusion of iohexol. Excretion of ALB, gamma-GTP, NAG and beta 2MG was significantly higher after infusion of diatrizoate than after iohexol. The urinary concentration of CRE was significantly lower after infusion of diatrizoate than after iohexol. The degree of renal damage after urography was no related to the appearance of allergy to the contrast agent or age of patient. Therefore, the non-ionic and slightly hyperosmolaric iohexol may be less toxic to the kidneys than the ionic and hypertonic diatrizoate. This nephrotoxicity after drip infused urography is thought to be related mainly to the osmolarity of contrast agent.

Adult↗
PubMed1991

[Transurethral intracavitary irradiation for carcinoma of the prostate].

This paper describes a new technique and preliminary clinical results of remote after-loading transurethral irradiation for cancer of the prostate. As of January 1986, twelve patients with adenocarcinoma of the prostate have been treated by our radiotherapy technique. Clinically, 3 patients were in stage B2, 3 in stage C, 3 in stage D1 and 3 in stage D2. These patients have been followed up for 13 to 33 months with a median follow-up period of 20.6 months. The dose of transurethral irradiation was 9-10 Gy. to the prostatic capsule and about 2 Gy. to the rectum in one procedure. We repeated this radiotherapy 3 to 4 times within an about 1-month period. Three patients in stage D1 and one patient in stage C received an additional external beam radiation (40 Gy.) to the entire pelvis. A needle biopsy was also performed every 4-6 months after irradiation. Local tumor response proved rapid and satisfactory as verified by a rectal examination and ultrasonography. The biopsies revealed a 70% negative rate within one year. The most common side effect was transient frequency observed in 7 patients. Severe complications such as incontinence, urethral stricture, or proctitis were not evident. This study suggests that intracavitary irradiation of cancer of the prostate is effective and safe. This method may have wider application.

Adenocarcinoma↗
PubMed1990

The inhibitory factors of hematopoiesis in chronic hemodialysis patients treated with recombinant human erythropoietin.

In order to clarify possible factors responsible for varying responses in uremic patients treated with recombinant human erythropoietin (rHuEPO), we determined the inhibitory effects of ten uremic sera on the erythroid progenitors (CFU-E) and erythroid bursts (BFU-E). We also measured plasma EPO titers, Fe, UIBC, ferritin, PTH-C, beta 2-microglobulin, and aluminum in all ten patients. The inhibitor of CFU-E but not BFU-E, was present in the serum of the single anemic patient whose recovery took longer after the administration of rHuEPO. He did not have such conditions as iron deficiency, excess of aluminum, or chronic inflammation. The remaining patients, who had no CFU-E or BFU-E inhibitors, were good responders to rHuEPO. In none of ten patients were there inhibitors of granulocyte-macrophage progenitors (CFU-GM) or any differences in the other parameters. Although the inhibitory factor of CFU-E can be overcome with a larger dose, its prior determination may be useful to set out minimal effective dose of EPO treatment.

Adult↗
PubMed1989

[Transurethral microwave coagulation of bladder cancer in elderly patients].

Since April 1985, 72 patients with bladder cancer have been treated by transurethral microwave coagulation (TUMC). In this procedure, tumors were irradiated with microwave energy of 100 watts for 2-16 minutes. A total of 20 patients were 70 years old or older, including 5 who were more than 80 years old. These 20 patients have been followed for 6 to 32 months with a median follow-up of 14.7 months. After TUMC, tumors completely disappeared endoscopically and histologically in all patients. Four patients had heterotopic recurrences. In all patients, serious complications were not seen during and after TUMC. Our clinical experience revealed that TUMC was the useful therapeutic method for bladder cancer in elderly or poor-risk patients. In this paper, we describe the technique of TUMC and preliminary clinical results.

Aged↗
PubMed1988

Combination therapy with microwave coagulation and intracavitary irradiation for bladder cancer. Technique and preliminary clinical results.

Twenty-five patients with transitional cell carcinoma of the bladder have been treated with combined therapy consisting of microwave regional coagulation and intracavitary irradiation. A remote-controlled after-loading system was utilized for the radiation therapy. The follow-up period ranged from 6 to 19 months with an average of 11.4 months. Tumor stages were Tis (n = 2), Ta or T1 (n = 17), T2 (n = 2), T3 (n = 3) and T4 (n = 1), and grades were G1 (n = 10), G2 (n = 11) and G3 (n = 4). In 23 patients (92%), there was no endoscopic or histologic evidence of tumor after the initial treatment. Heterotopic recurrences were found after 2 or 3 months in 3 patients who received microwave regional coagulation or intracavitary regional irradiation. Additional intracavitary whole bladder mucosal irradiation was performed for 10 patients with multiple tumors and frequent recurrent tumors. Nine patients had no recurrence (average follow-up 11 months). Our preliminary findings indicate that combination therapy of microwave coagulation and intracavitary irradiation is a useful treatment for bladder cancer.

Brachytherapy↗
PubMed1988

Microwave coagulation therapy for urinary bladder tumors.

A new device has been developed for microwave coagulation of urinary bladder tumors. Twenty-one patients with urinary bladder tumors were treated by irradiation with microwave energy of 2,450 MHz. Results were obtained as follows: (1) microwave coagulation was performed in 21 patients with transitional cell carcinoma of the urinary bladder. Excluding 4 patients who subsequently received radical cystectomy, 17 patients showed a complete response, although 2 patients subsequently developed recurrences in different parts of the bladder within the following several months. Histological examination of the excised specimen revealed complete eradication of the tumor in 2 patients. In the remaining 2 patients with high-stage tumor (T4), viable tumor cells were noted in the urethra or vaginal wall. (2) Although neither technical difficulties nor severe complications were encountered, transient urinary frequency and calcification of the bladder wall were noted. The results of this study indicate that microwave coagulation may be used in the treatment of both superficial and invasive tumors.

Aged↗
PubMed1985

[Clinical evaluation of cefmenoxime (CMX) for complicated urinary tract infection].

Cefmenoxime (CMX), a new semisynthetic antibiotic, was administrated in 29 cases diagnosed as complicated urinary tract infection. All patients received drip injection of 2 g (twice a day) for 5 days. Clinical results were excellent in 1 patient (3.4%), good in 15 patients (51.8%) and poor in 13 patients (44.8%). Effectiveness rate was 55.2%. In bacteriological response, out of 35 strains 27 (77.1%) strains were eradicated and 8 (22.9%) strains persisted. As for side effects, except one case of transient diarrhea after administration, no noteworthy reactions were observed. Laboratory abnormalities attributed to CMX treatment consisted of 4 cases of elevated serum transaminase and 2 cases of elevated serum creatinine.

Adult↗
PubMed1984

[Evaluation of the pelvioureteral function through an impedance urine bolus-metry].

New equipment based on field gradient principle for measurement of cross sectional area of ureteral urine bolus has been developed. Inside the probe consisted of a Fr.4 ureteral catheter, there are 4 ring impedance electrodes and a bipolar ring ureteromyographic electrode. Ex vivo experiments has proved high values in reliability and reproducibility of obtained cross sectional area of urine bolus through an impedance method. Following results have been obtained through animal and clinical experiments. As urine bolus passed through the impedance electrodes, impedance represented the cross sectional area of urine bolus. The ureteral activity corresponded to the increase of urine flow changed as follows, ureteral peristaltic frequency increased, cross sectional area of urine bolus increased, length of urine bolus increased, during maximum diuresis, peristaltic activity diminished and continuous flow presented through ureteral column. It will be useful method for experimental or clinical evaluation of ureteral function.

Adult↗
PubMedDate not supplied

Blood purification for postoperative liver failure with special reference to chronic hepatic support for those awaiting liver transplantation.

Blood purification, mainly plasma exchange (PE), was carried out for 13 cases of acute, and two cases of chronic postoperative liver failure. Four of thirteen acute cases (31%) survived. Although only one of eight with chronic liver disease survived, three of five without chronic liver disease survived. In most of those who lived, other organ failure occurred less often; total bilirubin and blood ammonia were less than 15 mg/dl and 200 micrograms/dl, respectively, before PE: and total bilirubin, blood ammonia, and branched chain amino acid/aromatic amino acid (BCAA/AAA) ratios recovered after five or fewer sessions of PE. Two chronic cases, treated for 1 and 4 years, respectively, were good candidates for liver or multiple organ transplantation. Although both died, PE was effective in reducing jaundice and in improving consciousness and general condition. Plasma exchange should be introduced early after assessing the changes in total bilirubin, blood ammonia, and coma grade in patients with acute postoperative liver failure. Plasma exchange could be useful as a chronic hepatic support system for those awaiting liver transplantation.

Acute Disease↗